


FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0941C1D1C1	Serial No. To Be Assigned		
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Rinderknecht et al.			
				Filing Date 04 Jan 2001	Group To Be Assigned		
U.S. PATENT DOCUMENTS							
Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
LPA ↓ LPA	* 1	4,000,098	28.12.76	Hofstee, B.	↓	↓	
	* 2	5,429,746	04.07.95	Shadle et al.	↓	↓	
	* 3	5,591,828	07.01.97	Bosslet, K. et al.	↓	↓	
	* 4	5,648,237	15.07.97	Carter, P.	↓	↓	
FOREIGN PATENT DOCUMENTS							
Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
LPA ↓ LPA	* 5	AU-B-57621/90	03.01.91	AUSTRALIA	↓	↓	
	* 6	WO 92/12993	06.08.92	PCT	↓	↓	
	* 7	WO 92/22653	23.12.92	PCT	↓	↓	
	* 8	WO 93/11161	10.06.93	PCT	↓	↓	
	* 9	WO 94/13804	23.06.94	PCT	↓	↓	
	* 10	WO 94/13806	23.06.94	PCT	↓	↓	
	* 11	WO 97/14719	24.04.97	PCT	↓	↓	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)							
LPA	* 12	Abe et al., "Purification of monoclonal antibodies with light-chain heterogeneity produced by mouse hybridomas raised with NS-1 myelomas: application of hydrophobic interaction high-performance liquid chromatography" <u>Journal of Biochemical and Biophysical Methods</u> 27:215-227 (1993)					
↓	* 13	Alfthan et al., "Purification of Labelled Antibodies by Hydrophobic Interaction Chromatography" <u>J. Chromatography</u> 470(385-389):385-389 (1989)					
↓	* 14	Axelsson K., "Bacterial Lipopolysaccharides and Glutathione Mixed Disulfides as Possible Contaminants of Human Growth Hormone Produced with the Use of E. coli K12" <u>Acta Chemica Scandinavica, Series B</u> 39(1):69-77 (1985)					
↓	* 15	Berkowitz et al., "Use of high-performance hydrophobic interaction chromatography for the determination of salting-out conditions of proteins" <u>Journal of Chromatography</u> 389:317-321 (1987)					
↓	* 16	Bridonneau et al., "Behaviour of human immunoglobulin G subclasses on thiophilic gels: comparison with hydrophobic interaction chromatography" <u>Journal of Chromatography</u> 616:197-204 (1993)					
↓	* 17	Bywater et al., "Desorption of Immunoglobulins from Protein A-Sepharose CL-4B under Mild Conditions" <u>Journal of Immunological Methods</u> 64:1-6 (1983)					
↓	* 18	Carter et al., "High level Escherichia coli expression and production of a bivalent humanized antibody fragment" <u>Bio/Technology</u> 10:163-167 (1992)					
↓	* 19	Cruse et al. <u>Illustrated Dictionary of Immunology</u> , CRC Press, Inc. pps. 18-19, 107-109 (1995)					
↓	* 20	Danielsson et al., "One-step purification of monoclonal IgG antibodies from mouse ascites" <u>Journal of Immunological Methods</u> 115:79-88 (1988)					
↓	* 21	Eigenbrot et al., "X-Ray Structures of Fragments From Binding and Nonbinding Versions of a Humanized Anti-CD18 Antibody: Structural Indications of the Key Role of V _H Residues 59 to 65" <u>Proteins: Structure, Function, and Genetics</u> 18:49-62 (1994)					
LPA	* 22	Fausnaugh et al., "Solute and Mobil Phase Contributions to Retention in Hydrophobic Interaction Chromatography of Proteins" <u>J. Chromatography</u> 359:131-146 (1986)					
Examiner					Date Considered		
					9/6/02		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0941C1D1C1	Serial No. To Be Assigned
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Rinderknecht et al.	
				Filing Date 04 Jan 2001	Group To Be Assigned
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
L	*23	Fendly et al., "The Extracellular Domain of HER2/neu Is a Potential Immunogen for Active Specific Immunotherapy of Breast Cancer" <u>Journal of Biological Response Modifiers</u> 9:449-455 (1990)			
	*24	Gagnon et al., "Method Development and Scale-Up in the Purification of Monoclonal Antibodies by Ion Exchange and Hydrophobic Interaction Chromatography" <u>Abstract of the Annual Meeting</u> (Abstract No. 0-4) (May 13, 1990)			
	*25	Hildreth et al., "A Human Lymphocyte-associated Antigen Involved in Cell-mediated Lympholysis" <u>European Journal of Immunology</u> 13:202-208 (1983)			
	*26	Holliger et al., "'Diabodies': Small bivalent and bispecific antibody fragments" <u>Proc. Natl. Acad. Sci. USA</u> 90:6444-6448 (Jul 1993)			
	*27	Hudziak et al., "p185HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <u>Molecular & Cellular Biology</u> 9(3):1165-1172 (Mar 1989)			
	*28	Inouye et al., "Fragmentation of mouse monoclonal antibodies of the immunoglobulin M class into F(ab') ₂ fragments and the application of the fragments to immunoassays" <u>Protein Engineering</u> (Abstract No. 44) pps. 1018-1019 (1993)			
	*29	Inouye et al., "One-Step Purification of F(ab') ₂ Fragments of Mouse Monoclonal Antibodies (Immunoglobulins G1 and M) by Hydrophobic Interaction HPLC" <u>Animal Cell Technology: Basic & Applied Aspects</u> 5:609-616 (1993)			
	*30	Inouye et al., "Single-step purification of F(ab') ₂ fragments of mouse monoclonal antibodies (immunoglobulins M) by hydrophobic interaction high-performance liquid chromatography using TSKgel Ether-5PW" <u>Journal of Biochemical and Biophysical Methods</u> 26:27-39 (1993)			
	*31	Johansson et al., "Purification of proteins by salt promoted adsorption chromatography" <u>Biol. Recombinant Microorg. Anim. Cells</u> (Oholo 34 Meeting) pps. 409-414 (1991)			
	*32	Kelley et al., "Antigen Binding thermodynamics and Antiproliferative Effects of Chimeric and Humanized anti-p185HER2 Antibody Fab Fragments" <u>Biochemistry</u> 31:5434-5441 (1992)			
	*33	Kurzban et al., "Purification of Bovine Liver Rhodanese by Low-pH Column Chromatography" <u>Protein Expression and Purification</u> 2:279-384 (1991)			
	*34	Mendelson et al., "Preparation and Characterization of Polyclonal and Monoclonal Antibodies against Human Aromatase Cytochrome P-450 (P-450 _{AROM}), and Their Use in its Purification" <u>Archives of Biochemistry & Biophysics</u> 243(2):480-491 (1985)			
	*35	Morimoto et al., "Single-step purification of F(ab') ₂ fragments of mouse monoclonal antibodies (immunoglobulins G1) by hydrophobic interaction high performance liquid chromatography using TSKgel Phenyl-5PW" <u>Journal of Biochemical and Biophysical Methods</u> 24:107-117 (1992)			
	*36	Nardella et al., "Nonimmunospecific Protein-Protein Interactions of IgG: Studies of the Binding of IgG to IgG Immunoabsorbents" <u>Journal of Immunology</u> 120(3):739-744 (1978)			
	*37	Nau et al., "The Role of Hydrophobic Interaction Chromatography in Antibody Purification - Optimization of Mobile Phase Conditions" <u>BioChromatography</u> 5(2):62-73 (1990)			
	*38	Neblock et al., "Conjugation and Evaluation of 7E3 X P4B6, a chemically Cross-Linked Bispecific F9ab') ₂ Antibody Which Inhibits Platelet Aggregation and Localizes Tissue Plasminogen Activator to the Platelet Surface" <u>Bioconjugate Chem</u> 3:126-131 (1992)			
	*39	Panka et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 85:3080-3084 (May 1988)			
	*40	Paulus, H., "Preparation and Biomedical Applications of Bispecific Antibodies" <u>Behring Inst. Mitt.</u> 78:118-132 (1985)			
	*41	Pavlu et al., "Rapid Purification of Monoclonal Antibodies by High-Performance Liquid Chromatography" <u>Journal of Chromatography</u> 359:449-460 (1986)			
W	*42	Rea et al., "The Rapid Development of Hydrophobic Interaction Chromatography Purification of a Murine Monoclonal IgG _{2a} F(ab') ₂ Fragment" <u>Journal of Cellular Biochemistry</u> (Abstract No. X1-206) Suppl.A:pg.50 (1993)			
Examiner				Date Considered	
				9/6/02	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

